Christopher L. Sorge

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

Adil Daud, Michelle T. Ashworth, Jonathan Strosberg et al. · Journal of Clinical Oncology · 2015 · 186 citations · Full text

Medicine, Oncology, Pharmacology +17

Early loss of large genomic DNA in vivo with accumulation of Ca2+ in the nucleus during acetaminophen-induced liver injury

Sidhartha D. Ray, Christopher L. Sorge, Judy L. Raucy et al. · Toxicology and Applied Pharmacology · 1990 · 120 citations

Life Sciences, Genetics, Molecular Biology +16

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

Judith E. Karp, B M Thomas, Jacqueline M. Greer et al. · Clinical Cancer Research · 2012 · 117 citations · Full text

Medicine, Oncology, Pharmacology +17

Ca(++)-activated DNA fragmentation and dimethylnitrosamine-induced hepatic necrosis: effects of Ca(++)-endonuclease and poly(ADP-ribose) polymerase inhibitors in mice.

Sidhartha D. Ray, Christopher L. Sorge, Lisa M. Kamendulis et al. · Journal of Pharmacology and Experimental Therapeutics · 1992 · 58 citations

Veterinary Medicine, Molecular Biology, Toxicology +17

Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 7. 8-Arylethyldipyridodiazepinones as Potent Broad-Spectrum Inhibitors of Wild-Type and Mutant Enzymes

Janice M. Klunder, MaryAnn Hoermann, Charles L. Cywin et al. · Journal of Medicinal Chemistry · 1998 · 34 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17